BioPharmSignal logoBioPharmSignal

Biotech News

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Acrivon Therapeutics (ACRV)Acrivon TherapeuticsConference / presentation

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive

Related news

ACRVAcrivon Therapeutics2026-08-12 20:05 EST

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

ACRVAcrivon Therapeutics2026-08-31 12:30 EST

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

LEGNLegend Biotech Corporation2026-09-01 12:00 EST

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

View all latest news

Acrivon Therapeutics

Generative Phosphoproteomics Platform Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines. ACR-368 ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and...

Recent company news

ACRVAcrivon Therapeutics2026-09-02 12:00 EST

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

ACRVAcrivon Therapeutics2026-09-02 12:00 EST

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

ACRVAcrivon Therapeutics2026-08-31 12:30 EST

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

ACRVAcrivon Therapeutics2026-08-31 12:30 EST

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

ACRVAcrivon Therapeutics2026-08-12 20:05 EST

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Stock data

Close
1.99 USD
Market cap
67.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States